

A

ADA, 20
Adenokanser, 50
Akciğer kanseri, 35,82,134,149
ALI, 134
ARDS, 98

B

Bosentan, 1
Bronkoplevral fistül, 27
Bronkoskopi, 27
Bulaşma, 140

C

COVID-19 pandemisi, 66
COVID-19, 53,75,113,140
CRP, 91

D

D-dimer, 91
Diffüz parankimal akciğer
hastalıkları, 103
Dispne, 66

E

ECMO, 98

F

Endobronşiyal tedavi, 27

F

Faktör V mutasyonu, 43
Favipiravir, 75

H

Hastanede yatış süresi, 12

İ

İlaç ilişkili akciğer hastalıkları, 103
İloprost, 1

K

Kapanma, 113
Karsinogenez, 149
Kaviter lezyon, 50
Kemoterapi, 82
Kısmi reversibilite, 125

L

Lobectomy, 98

M

%MMEF, 125
Malign plevral efüzyon, 155
Metastaz, 109
Metilen tetrahidrofolat redüktaz
mutasyonu, 43
Mezotelyoma, 109

N

n-butil siyanoakrilat, 27
Nitrofurantoin, 103
Nitrojen bileşikleri, 113
NLR, 134
Nötrfil-lenfosit oranı, 155

P

Pandemi, 140
Partikül madde, 113
Plazminojen aktivatör inhibitör-1
gen polimorfizmi, 43
Plörezi, 20
PLR, 134

Pnömoni, 12,75

Pozitron emisyon
tomografi-bilgisayarlı tomografi,
35

Prognostik faktör, 155
Prognostik indeks, 134
Protrombin gen mutasyonu, 43
Pulmoner emboli, 50,91
Pulmoner hipertansiyon, 1
Pulmoner rehabilitasyon, 66
Pulmoner tromboemboli, 43

S

Saçlı deri metastazı, 109
Sağkalım, 1,35
Septom, 53
Serum, 155
sGaw, 125

T

Takip, 53
Tedavi başarısı, 12
Telerehabilitasyon, 66
Tüberküloz, 20,149

U

Uyku kalitesi, 82

Y

Yaşam kalitesi, 66,82
Yaşlı, 12

A

ADA, 20
Adenocancer, 50
ALI, 134
ARDS, 98

B

Bosentan, 1
Bronchopleural fistula, 27
Bronchoscopy, 27

C

Cardiogenesis, 149
Cavitary lesion, 50
Chemotherapy, 82
COVID-19 pandemic, 66
COVID-19, 53,75,113,140
CRP, 91

D

D-dimer, 91
Diffuse parenchymal lung
diseases, 103
Drug-related lung diseases, 103
Duration of hospitalization, 12
Dyspnea, 66

E

ECMO, 98
Elderly, 12
Endobronchial treatment, 27

F

Factor V mutation, 43
Favipiravir, 75
Follow-up, 53

I

Iloprost, 1

L

Lobectomy, 98
Lockdown, 113
Lung cancer, 35,82,134,149

M

%MMEF, 125
Malignant pleural effusion, 155
Mesothelioma, 109
Metastasis, 109
Methylene tetrahydrofolate
reductase mutation, 43

N

n-butyl cyanoacrylate glue, 27
Neutrophil-to-lymphocyte ratio,
155
Nitrofurantoin, 103
Nitrogen compounds, 113
NLR, 134

P

Pandemic, 140
Partial reversibility, 125

Particulate matter, 113
Plasminogen activator inhibitor-1
gene polymorphisms, 43
Pleurisy, 20
PLR, 134
Pneumonia, 12,75
Positron emission
tomography-computed
tomography, 35
Prognostic factor, 155
Prognostic index, 134
Prothrombin gene mutation, 43
Pulmonary embolism, 43,50,91
Pulmonary hypertension, 1
Pulmonary rehabilitation, 66

Q

Quality of life, 66,82

S

Scalp metastasis, 109
Serum, 155
sGaw, 125
Sleep quality, 82
Survival, 1,35
Symptom, 53

T

Telerehabilitation, 66
Transmission, 140
Treatment success, 12
Tuberculosis, 20,149